Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

magazine

Bioventix’s sales smash expectations

The antibodies specialist says its Vitamin D antibody sales helped drive revenue growth
Thursday 19 Oct 2017 Author: Lisa-Marie Janes
Smaller Companies

Antibodies developer Bioventix (BVXP:AIM) achieved better than expected sales for its financial year to 30 June, up 31% to £7.2m. The results were particularly boosted by its Vitamin D antibody vitD3.5H10 for deficiency testing.

Full year earnings per share also beat expectations by 7%, which was driven by higher sales, gross margins and a lower tax charge.

Shareholders are being rewarded with a 40p per share special dividend, alongside a 31p normal dividend. (LMJ)

‹ Previous2017-10-19Next ›


19 Oct 2017

Download PDF

Page flip version

Important information:

These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.

Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.

Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.

The Shares team
Disclaimer

Issue contents

Big News

Editor's View

Feature

Great Ideas

Great Ideas Update

Investment Trusts

Larger Companies

Main Feature

Money Matters

Smaller Companies

Story In Numbers

Talking Point

Under The Bonnet

Week Ahead

Magazine archive


31 Jul 2025
24 Jul 2025
17 Jul 2025

10 Jul 2025
3 Jul 2025
26 Jun 2025

19 Jun 2025
12 Jun 2025
5 Jun 2025